![]() |
市场调查报告书
商品编码
1403433
2030 年肺计量计市场预测:按产品、技术、应用、最终用户和地区进行的全球分析Spirometers Market Forecasts to 2030 - Global Analysis By Product, By Technology, Application (Chronic Obstructive Pulmonary Disease, Asthma and Other Applications), End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球肺计量计市场规模为 11.552 亿美元,预计到 2030 年将达到 27.363 亿美元,预测期内复合年增长率为 13.1%。
肺计量计是医疗设备。这些设备测量重要的呼吸参数,例如肺活量、气流和呼吸肌肉效率。透过分析呼吸过程中空气运动的体积和速度,肺计量计可以帮助诊断和监测气喘、慢性阻塞性肺病(COPD) 和其他呼吸系统疾病,指导治疗并评估肺功能。
根据国家心肺血液研究所 2022 年 3 月发表的一篇论文,慢性阻塞性肺病是美国的首要死因,影响约 1,600 万美国。
全球气喘、慢性阻塞性肺病和肺纤维化等呼吸系统疾病的盛行率不断上升,增加了对评估肺功能的诊断工具的需求。肺计量计在诊断这些疾病、监测疾病进展和评估治疗效果方面发挥着至关重要的作用。随着人们越来越重视呼吸系统疾病的早期检测和管理,对肺活量测定设备的需求持续增长,推动市场扩张以满足不断增长的医疗保健需求。
在某些社区和医疗机构中,人们对呼吸健康评估的重要性以及肺活量测定法测试的好处认识不足。此外,获得医疗保健设施的差异限制了肺活量计在偏远和服务欠缺地区的使用。医疗保健专业人员培训不足也阻碍了采用。缺乏意识和有限的可及性阻碍了肺活量测定工具的普及,限制了其使用,并影响了市场成长。
人们对家庭医疗保健的日益青睐为肺计量计市场带来了机会。随着患者寻求方便的监测选择,便携式肺计量计透过允许在家庭环境中进行呼吸评估来应对这一趋势。这些设备可以让慢性呼吸道疾病患者定期监测肺功能,有助于及时介入并减少就诊次数。此外,向居家照护的转变,符合患者对独立性和便利性的偏好,正在推动对便携式肺活量测定解决方案的需求,提供传统医疗机构之外的呼吸监测选项,这将扩大市场。
当肺活量测定设备与数位系统连接并整合以进行资料储存和分析时,潜在违规、诈欺的存取和资料滥用的风险就会增加。在肺活量测定期间收集的患者健康资讯需要受到保护以确保机密性。如果无法解决这些问题,就会削弱患者的信任,阻碍采用,并受到监管审查。
在 COVID-19 爆发期间,肺计量计面临挑战和适应。最初,人们对肺活量测定过程中气溶胶的产生产生了担忧,由于感染风险而影响了其使用。然而,随着了解的增加,已经建立了协议来确保安全的肺活量测定性能,特别是对于关键的呼吸评估。此外,疫情加速了远端监控和远端医疗解决方案的开发,并促进了肺计量计与虚拟医疗机构的整合。
在预测期内,流量测量领域由于其在评估呼吸功能方面的基本作用,预计将主导肺计量计市场。流量测量提供有关吸气和呼气期间空气移动速度的重要资料,可用于诊断和监测呼吸系统疾病。此外,流量测量的准确性和灵敏度极大地有助于准确的呼吸评估,因此是肺计量计市场中该细分市场预期主导地位的关键驱动因素。
在预测期内,医院部门可能会显着成长。该医院仍然是综合医疗保健服务的主要中心,包括呼吸系统诊断和治疗。随着呼吸系统疾病盛行率的上升,医院对先进肺活量测定设备的需求不断增加。此外,对呼吸系统疾病的早期检测和管理的日益关注增加了医院环境中对准确诊断工具的需求。此外,技术进步以及肺活量计与医院资讯系统的整合进一步推动了这一领域的成长。
由于先进的医疗基础设施、高昂的医疗成本以及对呼吸健康的高度重视,北美在肺计量计市场中占据了最大的市场占有率。此外,意识的提高、有利的报销政策以及肺活量测定设备的技术进步也促进了市场的成长。此外,北美呼吸系统疾病的高盛行率和对医疗保健创新的积极承诺,使该地区成为关键的市场领导者,在肺活量测定解决方案的采用和实施中占有很大份额。我是。
由于呼吸系统疾病盛行率上升和老年人口增加,预计亚太地区肺计量计市场将强劲成长。此外,医疗支出的增加、医疗基础设施的改善以及呼吸健康意识的提高正在进一步推动市场。此外,技术进步、便携式和负担得起的肺活量测定设备的采用以及农村地区医疗保健服务的扩大正在推动亚太地区的市场成长。
According to Stratistics MRC, the Global Spirometers Market is accounted for $1155.2 million in 2023 and is expected to reach $2736.3 million by 2030 growing at a CAGR of 13.1% during the forecast period. Spirometers are medical devices used to measure lung function by assessing the volume of air inhaled or exhaled. These instruments gauge vital respiratory parameters, including lung capacity, airflow and the efficiency of respiratory muscles. By analyzing the volume and speed of air movement during breathing maneuvers, spirometers aid in diagnosing and monitoring conditions like asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders, guiding treatment and evaluating pulmonary function.
According to an article published by the National Heart, Lung, and Blood Institute in March 2022, COPD is the leading cause of death in the U.S., affecting about 16 million Americans.
Owing to the increasing prevalence of respiratory diseases like asthma, COPD, and pulmonary fibrosis worldwide, there's a heightened demand for diagnostic tools to assess lung function. Spirometers play a pivotal role in diagnosing these ailments, monitoring disease progression, and evaluating treatment efficacy. With a rising emphasis on early detection and management of respiratory disorders, the demand for spirometry devices continues to grow, driving market expansion to cater to the escalating healthcare needs.
In certain regions or healthcare settings, there's inadequate awareness regarding the importance of respiratory health assessment and the benefits of spirometry testing. Additionally, disparities in access to healthcare facilities restrict the availability of spirometers in remote or underserved areas. Insufficient training among healthcare professionals further impedes adoption. This lack of awareness and limited accessibility hinders widespread adoption of spirometry tools, constraining their usage and impacting market growth.
The increasing inclination towards home healthcare presents an opportunity in the spirometers market. As patients seek convenient monitoring options, portable spirometers cater to this trend by enabling respiratory assessments in home settings. These devices allow individuals with chronic respiratory conditions to regularly monitor lung function, facilitating timely intervention and reducing hospital visits. Moreover, the shift towards home-based care aligns with patient preferences for independence and convenience, driving the demand for portable spirometry solutions and expanding the market by offering accessible respiratory monitoring options outside traditional healthcare facilities.
When spirometry devices are connected and integrated with digital systems for data storage and analysis, there's a heightened risk of potential breaches, unauthorized access or data misuse. Patient health information collected during spirometry tests requires protection to ensure confidentiality. Failure to address these concerns can erode patient trust, hinder adoption, and lead to regulatory scrutiny.
During the COVID-19 pandemic, spirometers faced challenges and adaptations. Initially, concerns arose regarding aerosol generation during spirometry tests, impacting their use due to infection risks. However, as understanding evolved, protocols were established to ensure safe spirometry practices, especially for essential respiratory assessments. Additionally, the pandemic accelerated the development of remote monitoring and telemedicine solutions, fostering the integration of spirometers into virtual healthcare setups, allowing continued respiratory monitoring and management while minimizing in-person contact and enhancing remote patient care.
Over the forecast period, the flow measurement segment is anticipated to dominate the spirometers market, attributed to its fundamental role in assessing respiratory function. Flow measurements provide crucial data on the rate of air movement during inhalation and exhalation, aiding in the diagnosis and monitoring of respiratory conditions. Moreover, the precision and sensitivity of flow measurements contribute significantly to accurate respiratory assessments, making them a key driver for the segment's anticipated dominance in the spirometers market.
During the forecast period, the hospitals segment is poised to witness significant growth. Hospitals remain the primary centers for comprehensive healthcare services, including respiratory diagnostics and treatment. With a rising incidence of respiratory ailments, hospitals demand for advanced spirometry equipment is escalating. Additionally, the increasing focus on early detection and management of respiratory diseases augments the need for accurate diagnostic tools in hospital settings. Moreover, technological advancements and the integration of spirometers into hospital information systems further drive the growth of this segment.
North America is set to secure the largest market share in the spirometers market owing to its advanced healthcare infrastructure, high healthcare expenditure and robust focus on respiratory health. Additionally, increased awareness, favorable reimbursement policies and technological advancements in spirometry devices contribute to the market's growth. Furthermore, a high prevalence of respiratory diseases and a proactive approach to healthcare innovation in North America position the region as a key market leader, with a significant share in the adoption and implementation of spirometry solutions.
Asia Pacific is poised to register robust growth in the spirometers market owing to the region's rising prevalence of respiratory disorders coupled with a growing geriatric population. Additionally, increasing healthcare expenditure, improving healthcare infrastructure and a surge in awareness regarding respiratory health further drive the market. Moreover, technological advancements, the adoption of portable and affordable spirometry devices and the expansion of healthcare access to rural areas foster the market's growth in the Asia Pacific region.
Some of the key players in spirometers market include Benson Medical Instruments, Bionet America, Inc., CareFusion, Cosmed Srl, Fukuda Sangyo Co., Ltd., Future Med Devices Pvt. Ltd., Medikro Oy, MGC Diagnostics Corporation, Midmark Corporation, Morgan Scientific Inc., NDD Medical Technologies, Nihon Kohden Corporation, Schiller AG, SDI Diagnostics, Vitalograph Ltd and Welch Allyn, Inc.
In September 2023, Alveofit (Roundworks Technologies) has received approval from the US Food and Drug Administration (FDA) for its portable digital spirometer, alveoair. With this approval, the company plans to start distributing the product in the US.
In January 2023, Koneksa, a healthcare technology company developing evidence-based validated digital biomarkers, today announced the launch of a clinical study comparing the treatment effect between at-home mobile spirometry using digital biomarkers and in-clinic spirometry in patients with moderate asthma on long-acting beta-agonist (LABA) treatment.
In September 2022, RxCap, Inc. collaborated with ZEPHYRx to connect the ZEPHYRx online spirometry platform to RxCap's remote surveillance platform. RxCap's corporate customers, who include providers and payers, may now track the lung health of their clients and patients who have severe respiratory diseases.